Myeloma Patient Registered to Run His 90th Marathon with Cancer

Don Wright didn't let his 2003 myeloma diagnosis stop him in tracks. This weekend, Don is registered to run his 90th marathon with myeloma in Washington, D.C. The 74-year old says he's managed his cancer for seven of the last twelve years with oral cancer therapies, but knows “multiple myeloma cannot be cured, so I am counting on continuing progress, research and access to the latest treatments to provide the next remission and the remission after that.”
Source: International Myeloma Foundation - Category: Hematology Source Type: news

Related Links:

Publication date: 15 October 2018 Source:Biosensors and Bioelectronics, Volume 117 Author(s): Shaowei Ding, Suprem R. Das, Benjamin J. Brownlee, Kshama Parate, Taylor M. Davis, Loreen R. Stromberg, Edward K.L. Chan, Joseph Katz, Brian D. Iverson, Jonathan C. Claussen Vertically aligned carbon nanotube array (VANTA) coatings have recently garnered significant attention due in part to their unique material properties including light absorption, chemical inertness, and electrical conductivity. Herein we report the first use of VANTAs grown via chemical vapor deposition in a 2D interdigitated electrode (IDE) footprint with a ...
Source: Biosensors and Bioelectronics - Category: Biotechnology Source Type: research
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) worsens oral health-related quality of life. Most BRONJ occurs in multiple myeloma or metastatic breast cancer patients treated with bisphosphonate/chemotherapeutic combination therapies. Cyclophosphamide (CY), an alkylating chemotherapeutic drug, is used to treat multiple myeloma, although its use has been recently reduced. The aim of this study was to clarify the effects of CY dose on tooth extraction socket healing when CY is used with or without bisphosphonate in mice.
Source: Bone - Category: Orthopaedics Authors: Tags: Full Length Article Source Type: research
Pomalidomide promotes chemosensitization of pancreatic cancer by inhibition of NF-κB. Oncotarget. 2018 Mar 16;9(20):15292-15301 Authors: Shirai Y, Saito N, Uwagawa T, Shiba H, Horiuchi T, Iwase R, Haruki K, Ohashi T, Yanaga K Abstract Introduction: Nuclear factor κB (NF-κB) plays an important role in cancer progression and causes therapeutic resistance to chemotherapy. Pomalidomide, a third-generation immunomodulating drug derived from thalidomide, has been approved for uncontrolled multiple myeloma. We hypothesized that pomalidomide may inhibit the anticancer agent-induced NF-κ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
We reported a case of MCD who received chemotherapy by ECHOP with unsatisfactory outcome and then oral administration with thalidomide combined with prednisone without disease progression after therapy. After 3 years, his MCD turned into multiple myeloma (MM) and accompanied by obvious response to combination of thalidomide with prednisone. Nowadays, there is no standard of therapy yet established for MCD. We successfully treated one such patient and found thalidomide based therapy may have a significant effect on MCD. We also proposed further researches with therapeutic potential about thalidomide for MCD. PMID:...
Source: Cancer Biology and Therapy - Category: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research
This study carried out the initial validation of documents to standardize the pharmaceutical counseling for patients treated for myeloma so that it can be reproduced from one patient to another regardless of the pharmacist, by standardizing the information issued. This study needs to be completed by a final validation in myeloma patients, free from oral anticancer therapies. PMID: 29573809 [PubMed - as supplied by publisher]
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Tags: Bull Cancer Source Type: research
In this report, we describe our retrospective experience, in 18 patients, with the administration of lenalidomide 25 mg every other day for patients with MM and RI. The overall response ratio was 66.5%. More than half (61.1%) of the patients had a renal response. The median progression-free survival was 8 months (range: 3–18 months). No serious adverse event occurred during treatment, and it was never necessary to disrupt or delay treatment for toxicity. These preliminary observations point to a significant therapeutic effect of lenalidomide, at the dose of 25 mg every other day for 21 days, with logist...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Clinical Reports Source Type: research
CONCLUSIONSThe early release of SEER data continues to be useful as a preliminary estimate of the most current cancer incidence trends. Cancer 2018. © 2018 American Cancer Society.
Source: Cancer - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research
This study will provide evidence to better define post-relapse treatment in MM.Trial registrationISRCTN,ISRCTN10038996. Registered on 15 December 2016.
Source: Trials - Category: Research Source Type: clinical trials
Abstract The term 'economy class syndrome' refers to the occurrence of thrombotic events during long-haul flights that mainly occur in passengers in the economy class of the aircraft. This syndrome results from several factors related to the aircraft cabin (immobilization, hypobaric hypoxia and low humidity) and the passenger (body mass index, thrombophilia, oral contraceptives or hormone replacement therapy, cancer), acting together to predispose to excessive blood coagulation, which can result in venous thromboembolism. Several risk factors, both genetic and acquired, are associated with venous thromboembolism. The most ...
Source: Revista Brasileira de Hematologia e Hemoterapia - Category: Hematology Source Type: research
Positive Overall Survival Data From Phase 3 ASPIRE Trial on KYPROLIS® (Carfilzomib) in Relapsed Multiple Myeloma to be Highlighted in Oral Presentation Results From Several Abstracts Highlight the Potential of Amgen's Bispecific T Cell Engager (BiTE®) Platform as an Innovative Approach to Treating Blood Cancers FDA Grants Priority Review for BLINCYTO (Blinatumomab) Supplemental Biologics License Application in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia THOUSAND OAKS, Calif., Dec. 7, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new clinical data and analyses from 33...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Therapy | Hematology | Myeloma | Oral Cancer